

DAFTAR PUSTAKA

- Forette, F. *et al.* (1998) "Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial.," *Lancet (London, England)*, 352(9137), hal. 1347–1351. doi: 10.1016/s0140-6736(98)03086-4.
- Gaidhane, S. *et al.* (2014) "Essential hypertension and cognitive function in elderly," *Journal of Medicine and Public Health*, 3(2).
- Hanon, O. *et al.* (2006) "Relationship between antihypertensive drug therapy and cognitive function in elderly hypertensive patients with memory complaints.," *Journal of hypertension*, 24(10), hal. 2101–2107. doi: 10.1097/01.hjh.0000244961.69985.05.
- Kalaria, R. N. dan Ballard, C. (1999) "Overlap between pathology of Alzheimer disease and vascular dementia," *Alzheimer Disease & Associated Disorders*, 13, hal. S115–S123. doi: 10.1097/00002093-199912003-00017.
- Mills, K. T. *et al.* (2016) "Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries," *Circulation*, 134(6), hal. 441–450. doi: 10.1161/CIRCULATIONAHA.115.01891.
- Paran, E., Anson, O. dan Lowenthal, D. T. (2010) "Cognitive function and antihypertensive treatment in the elderly: a 6-year follow-up study.," *American journal of therapeutics*, 17(4), hal. 358–364. doi: 10.1097/MJT.0b013e3181bf325c.
- Roth, G. A. *et al.* (2018) "Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017," *The Lancet*, 392(10159), hal. 1736–1788. doi: 10.1016/S0140-6736(18)32203-7.
- Sharp, S. I. *et al.* (2011) "Hypertension is a potential risk factor for vascular dementia: systematic review," *International journal of geriatric psychiatry*, 26(7), hal. 661–669. doi: 10.1002/gps.2572.
- Stanaway, J. D. *et al.* (2018) "Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease," *The Lancet*, 392(10159), hal. 1923–1994. doi: 10.1016/S0140-6736(18)32225-6.
- Trompet, S. *et al.* (2008) "Use of calcium antagonists and cognitive decline in old age. The Leiden 85-plus study.," *Neurobiology of aging*, 29(2), hal. 306–308. doi: 10.1016/j.neurobiolaging.2006.10.006.
- Waldstein, S. R. dan Katzel, L. I. (2001) "Hypertension and cognitive function," in *Neuropsychology of cardiovascular disease*. US: Psychology Press, hal. 31–52. doi: 10.4324/9781410600981.

- Abadi, K. *et al.* (2013) “Hipertensi dan Risiko Mild Cognitive Impairment pada Pasien Usia Lanjut,” *Kesmas: National Public Health Journal*, 8(3), hal. 115–118. doi: 10.21109/kesmas.v8i3.354.
- Chakraborty, R. K. dan Hamilton, R. J. (2024) *Calcium Channel Blocker Toxicity.*, *National Center for Biotechnology Information (NCBI)*. Treasure Island (FL). Tersedia pada: <https://pubmed.ncbi.nlm.nih.gov/30725832/> (Diakses: 14 Agustus 2024).
- Haider, A., Spurling, B. C. dan Sánchez-Manso, J. C. (2023) *Lewy Body Dementia*, *National Center for Biotechnology Information (NCBI)*. Tersedia pada: <https://www.ncbi.nlm.nih.gov/books/NBK482441/> (Diakses: 8 Agustus 2024).
- Hegde, S., Ahmed, I. dan Aeddula, N. R. (2023) *Secondary Hypertension*, *National Center for Biotechnology Information (NCBI)*. Tersedia pada: <https://www.ncbi.nlm.nih.gov/books/NBK544305/> (Diakses: 14 Agustus 2024).
- Iqbal, A. M. dan Jamal, S. F. (2023) *Essential Hypertension*, *National Center for Biotechnology Information (NCBI)*. Tersedia pada: <https://www.ncbi.nlm.nih.gov/books/NBK539859/> (Diakses: 14 Agustus 2024).
- Khan, I. dan Jesus, O. De (2023) *Frontotemporal Lobe Dementia*, *National Center for Biotechnology Information (NCBI)*. Tersedia pada: <https://www.ncbi.nlm.nih.gov/books/NBK559286/> (Diakses: 14 Agustus 2024).
- Lennon, M. J. *et al.* (2023) “Use of Antihypertensives, Blood Pressure, and Estimated Risk of Dementia in Late Life: An Individual Participant Data Meta-Analysis.” *JAMA network open*, 6(9), hal. e2333353. doi: 10.1001/jamanetworkopen.2023.33353.
- McKeever, R. G., Patel, P. dan Hamilton, R. J. (2024) *Calcium Channel Blockers.*, *National Center for Biotechnology Information (NCBI)*. Treasure Island (FL). Tersedia pada: <https://pubmed.ncbi.nlm.nih.gov/29494080/> (Diakses: 14 Agustus 2024).
- Nagai, M., Hoshide, S. dan Kario, K. (2010) “Hypertension and dementia.” *American journal of hypertension*, 23(2), hal. 116–124. doi: 10.1038/ajh.2009.212.
- Nichols, E. (2022) “Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019,” *The Lancet. Public health*, 7(2), hal. e105–e125. doi: 10.1016/S2468-2667(21)00249-8.
- Reitz, C. *et al.* (2007) “Hypertension and the risk of mild cognitive impairment.” *Archives of neurology*, 64(12), hal. 1734–1740. doi: 10.1001/archneur.64.12.1734.
- Sharma, S., Hashmi, M. F. dan Bhattacharya, P. T. (2023) *Hypotension*, *National Center for Biotechnology Information (NCBI)*. Tersedia pada: <https://www.ncbi.nlm.nih.gov/books/NBK499961/> (Diakses: 5 Agustus 2024).
- Sperandei, S. (2014) “Understanding logistic regression analysis.” *Biochemia medica*, 24(1), hal. 12–18. doi: 10.11613/BM.2014.003.

- Suriastuti, N. W. *et al.* (2020) "Prevalence and risk factors of dementia and caregiver's knowledge of the early symptoms of alzheimer's disease," *Aging Medicine and Healthcare*, 11(2), hal. 60–66. doi: 10.33879/amh.2020.065-1811.032.
- Tanne, J. H. (2003) "US guidelines say blood pressure of 120/80 mm Hg is not 'normal'.,," *BMJ (Clinical research ed.)*. England, hal. 1104. doi: 10.1136/bmj.326.7399.1104-a.
- Turana, Y. (2018) *Diagnosis , klasifikasi Hipertensi, Indonesian Society of Hypertension FK UNIKA AtmaJaya*. Tersedia pada: https://p2ptm.kemkes.go.id/uploads/VHcrbkVobjRzUDN3UCs4eUJ0dVBndz09/2018/05/Diagnosis_Klasifikasi_Hipertensi_Yuda_Turana_Indonesian_Society_of_Hypertension_FK_Unika_Atmajaya.pdf (Diakses: 13 Agustus 2024).
- Unger, T. *et al.* (2020) "International Society of Hypertension Global Hypertension Practice Guidelines," *Hypertension (Dallas, Tex. : 1979)*, 75(6), hal. 1334–1357. doi: 10.1161/HYPERTENSIONAHA.120.15026.
- Wu, C.-L. dan Wen, S.-H. (2016) "A 10-year follow-up study of the association between calcium channel blocker use and the risk of dementia in elderly hypertensive patients.,," *Medicine*, 95(32), hal. e4593. doi: 10.1097/MD.0000000000004593.
- ANALISIS PARAMETER FUNGSI GINJAL DAN EFEKTIVITAS ANTIHIPERTENSI PADA PASIEN RAWAT INAP HIPERTENSI DI RSUD KOTA MADIUN. (n.d.). *Duta Pharma Journal*, 1(1 SE-Articles), 1–11. <https://doi.org/10.47701/djp.v1i1.1187>
- Bulqiah, A., Suprpti, B., Ardiana, S. muti, Alsagaff, M. Y., & Suharjono. (2023). Penggunaan Obat Pada Pasien Hipertensi Rawat Jalan. *Window of Health : Jurnal Kesehatan*, 6(2), 119–130. <https://doi.org/10.33096/woh.vi.66>
- Departemen Kesehatan RI. (2006). Pharmaceutical Care untuk Penyakit Hipertensi. *Pharmaceutical Care Untuk Pasien Penyakit Arthritis Rematik*, 53–80.
- Diwati, A., & Sofyan, O. (2023). Profil dan Rasionalitas Penggunaan Obat Antihipertensi Pada Pasien Hipertensi Di Fasilitas Kesehatan Tingkat Pertama Periode Mei - Juli 2021. *Majalah Farmaseutik*, 19(1), 1. <https://doi.org/10.22146/farmaseutik.v19i1.80153>
- Heroweti, J., & Rokhmawati, I. (2023). Analisis Efektivitas Biaya Kombinasi CCB-ACEI dan CCB-ARB pada Pasien Hipertensi dengan Penyerta DM Tipe II. *Jurnal Mandala Pharmacon Indonesia*, 9(1 SE-Original Articles), 94–99. <https://doi.org/10.35311/jmpi.v9i1.311>
- Hwang, D., Kim, S., Choi, H., Oh, I. H., Kim, B. S., Choi, H. R., Kim, S. Y., & Won, C. W. (2016). Calcium-channel blockers and dementia risk in older adults – National health insurance service – Senior cohort (2002–2013). *Circulation Journal*, 80(11), 2336–2342. <https://doi.org/10.1253/circj.CJ-16-0692>
- Kopecky, B. J., Liang, R., & Bao, J. (2014). T-type calcium channel blockers as neuroprotective agents. *Pflugers Archiv European Journal of Physiology*, 466(4), 757–765. <https://doi.org/10.1007/s00424-014-1454-x>
- Lovell, M. A., Abner, E., Kryscio, R., Xu, L., Fister, S. X., & Lynn, B. C. (2015). Calcium

Channel Blockers, Progression to Dementia, and Effects on Amyloid Beta Peptide Production. *Oxidative Medicine and Cellular Longevity*, 2015. <https://doi.org/10.1155/2015/787805>

Oktianti, D., Septina Widyadewi, P. P., & Wati, D. R. (2023). Identifikasi Potensi Interaksi Obat Antihipertensi Pada Pasien Rawat Jalan Di Rs X Denpasar Periode Oktober-Desember 2021. *INPHARNMED Journal (Indonesian Pharmacy and Natural Medicine Journal)*, 6(2), 82. <https://doi.org/10.21927/inpharnmed.v6i2.2578>

PERHI. (2024). Panduan Pengenalan dan Tatalaksana Hipertensi Resisten Di Indonesia. *Perhimpunan Dokter Hipertensi Indonesia*, 1.

Peters, R., Beckett, N., Forette, F., Tuomilehto, J., Clarke, R., Ritchie, C., Waldman, A., Walton, I., Poulter, R., Ma, S., Comsa, M., Burch, L., Fletcher, A., & Bulpitt, C. (2008). Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. *The Lancet Neurology*, 7(8), 683–689. [https://doi.org/10.1016/S1474-4422\(08\)70143-1](https://doi.org/10.1016/S1474-4422(08)70143-1)

Polopadang, Y., Mongi, J., Maarisit, W., & Karauwan, F. (2021). Pola Peresepan Penggunaan Obat Antihipertensi di UPTD Puskesmas Airmadidi. *Jurnal Biofarmasetikal Tropi*, 4(1), 97–101. <https://doi.org/10.55724/j.biofar.trop.v4i1.315>

Pratama, F., Feladita, N., & Primadiamanti, A. (2023). Evaluasi Penggunaan Obat Antihipertensi Pada Pasien Hipertensi Rawat Jalan Di Puskesmas Rawajitu. *Jurnal Farmasi Malahayati*, 6(1), 76–89. <https://doi.org/10.33024/jfm.v6i1.8860>

Rahmawati, W. T., An, A., & Raharjo, W. (2020). Description of Hypertension With Vascular Demensia in Non Hemorrhagic Stroke Patients At the Neurology Clinic Sultan Syarif Mohamad Alkadrie Regional Public Hospital Pontianak. *Jurnal Kedokteran Dan Kesehatan : Publikasi Ilmiah Fakultas Kedokteran Universitas Sriwijaya*, 7(2), 130–137. <https://doi.org/10.32539/jkk.v7i2.11110>

Sinata, N., & Aisyah Rahmadani, S. (2021). Gambaran Penggunaan Antihipertensi Pada Pasien Rawat Jalan Di Puskesmas Sidomulyo Pekanbaru Tahun 2020. *Jurnal Kesehatan Tambusai*, 2(4), 348–353. <https://doi.org/10.31004/jkt.v2i4.3198>

Wulandari, A. (2022). Evaluasi Pemberian Dan Penggunaan Obat Antihipertensi Pada Pasien Lansia Di Puskesmas Sukarami Palembang. *INPHARNMED Journal (Indonesian Pharmacy and Natural Medicine Journal)*, 5(2), 17. <https://doi.org/10.21927/inpharnmed.v5i2.1919>

Barone, F. C., Lysko, P. G., Price, W. J., Feuerstein, G., Al-Baracani, K. A., Benham, C. D., Harrison, D. C., Harries, M. H., Bailey, S. J., & Hunter, A. J. (1995). SB 201823-A Antagonizes Calcium Currents in Central Neurons and Reduces the Effects of Focal Ischemia in Rats and Mice. *Stroke*, 26(9), 1683–1690. <https://doi.org/10.1161/01.STR.26.9.1683>

Barone, F. C., Price, W. J., Jakobsen, P., Sheardown, M. J., & Feuerstein, G. (1994).

Pharmacological profile of a novel neuronal calcium channel blocker includes reduced cerebral damage and neurological deficits in rat focal ischemia. *Pharmacology Biochemistry and Behavior*, 48(1), 77–85. [https://doi.org/https://doi.org/10.1016/0091-3057\(94\)90501-0](https://doi.org/https://doi.org/10.1016/0091-3057(94)90501-0)

Benham, C. D., Brown, T. H., Cooper, D. G., Evans, M. L., Harries, M. H., Herdon, H. J., Meakin, J. E., Murkitt, K. L., Patel, S. R., Roberts, J. C., Rothaul, A. L., Smith, S. J., Wood, N., & Hunter, A. J. (1993). SB 201823-A, a neuronal Ca²⁺ antagonist is neuroprotective in two models of cerebral ischaemia. *Neuropharmacology*, 32(11), 1249–1257. [https://doi.org/https://doi.org/10.1016/0028-3908\(93\)90019-Y](https://doi.org/https://doi.org/10.1016/0028-3908(93)90019-Y)

Maxwell, C. J., & Hogan, D. B. (2010). Antihypertensive agents and prevention of dementia. *BMJ*, 340. <https://doi.org/10.1136/bmj.b5409>

